Glimepiride
 | |
| Clinical data | |
|---|---|
| Trade names | Amaryl, others |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a696016 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | 100% |
| Protein binding | >99.5% |
| Metabolism | Complete Liver (1st stage through CYP2C9) |
| Onset of action | 2–3 hours |
| Elimination half-life | 5–8 hours |
| Duration of action | 24 hours |
| Excretion | Urine (~60%), feces (~40%) |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.170.771 |
| Chemical and physical data | |
| Formula | C24H34N4O5S |
| Molar mass | 490.62 g·mol−1 |
| 3D model (JSmol) | |
| Melting point | 207 °C (405 °F) |
| |
| |
  (what is this?) (verify) | |
Glimepiride is an antidiabetic medication within the sulfonylurea class, primarily prescribed for the management of type 2 diabetes.[1][2] It is regarded as a second-line option compared to metformin, due to metformin's well-established safety and efficacy.[1] Use of glimepiride is recommended in conjunction with lifestyle modifications such as diet and exercise.[1] It is taken by mouth,[1] reaching a peak effect within three hours and lasting for about a day.[1]
Common side effects include headache, nausea, and dizziness.[1] Serious side effects may include low blood sugar.[1] Use during pregnancy and breastfeeding is not recommended.[3] It works predominantly by increasing the amount of insulin released from the pancreas.[1] It is classified as a second-generation sulfonylurea.[4]
Glimepiride was patented in 1979 and approved for medical use in 1995.[5] It is available as a generic medication.[2] In 2022, it was the 64th most commonly prescribed medication in the United States, with more than 10 million prescriptions.[6][7]
Medical uses
[edit]
Glimepiride is indicated to treat type 2 diabetes; its mode of action is to increase insulin secretion by the pancreas. However it requires adequate insulin synthesis as prerequisite to treat appropriately. It is not used for type 1 diabetes because in type 1 diabetes the pancreas is not able to produce insulin.[8]
Contraindications
[edit]Its use is contraindicated in patients with hypersensitivity to glimepiride or other sulfonylureas.
Adverse effects
[edit]Side effects from taking glimepiride include gastrointestinal tract (GI) disturbances, occasional allergic reactions, and rarely blood production disorders including thrombocytopenia, leukopenia, and hemolytic anemia. In the initial weeks of treatment, the risk of hypoglycemia may be increased. Alcohol consumption and exposure to sunlight should be restricted because they can worsen side effects.[8]
Interactions
[edit]Nonsteroidal anti-inflammatory drugs (such as salicylates), sulfonamides, chloramphenicol, coumadin and probenecid may potentiate the hypoglycemic action of glimepiride. Thiazides, other diuretics, phothiazides, thyroid products, oral contraceptives, and phenytoin tend to produce hyperglycemia.
Mechanism of action
[edit]Like all sulfonylureas, glimepiride acts as an insulin secretagogue.[9] It lowers blood sugar by stimulating the release of insulin by pancreatic beta cells and by inducing increased activity of intracellular insulin receptors.
Not all secondary sulfonylureas have the same risk of hypoglycemia. Glibenclamide (glyburide) is associated with an incidence of hypoglycemia of up to 20–30%, compared to as low as 2% to 4% with glimepiride. Glibenclamide also interferes with the normal homeostatic suppression of insulin secretion in reaction to hypoglycemia, whereas glimepiride does not. Also, glibenclamide diminishes glucagon secretion in reaction to hypoglycemia, whereas glimepiride does not.[10]
Pharmacokinetics
[edit]Gastrointestinal absorption is complete, with no interference from meals. Significant absorption can occur within one hour, and distribution is throughout the body, 99.5% bound to plasma protein. Metabolism is by oxidative biotransformation, it is hepatic and complete. First, the medication is metabolized to M1 metabolite by CYP2C9. M1 possesses about 1⁄3 of pharmacological activity of glimepiride, yet it is unknown if this results in clinically meaningful effect on blood glucose. M1 is further metabolized to M2 metabolite by cytosolic enzymes. M2 is pharmacologically inactive. Excretion in the urine is about 65%, and the remainder is excreted in the feces.
References
[edit]- ^ a b c d e f g h "Glimepiride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
- ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 693. ISBN 9780857113382.
- ^ "Glimepiride Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
- ^ Davis SN (2004). "The role of glimepiride in the effective management of Type 2 diabetes". J. Diabetes Complicat. 18 (6): 367–76. doi:10.1016/j.jdiacomp.2004.07.001. PMID 15531188.
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 449. ISBN 9783527607495. Archived from the original on 10 January 2023. Retrieved 7 September 2020.
- ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
- ^ "Glimepiride Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
- ^ a b "Glimepiride: MedlinePlus Drug Information". nih.gov. Archived from the original on 5 July 2016. Retrieved 21 March 2018.
- ^ Nissen SE, Nicholls SJ, Wolski K, et al. (April 2008). "Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial". JAMA. 299 (13): 1561–73. doi:10.1001/jama.299.13.1561. PMID 18378631.
- ^ Davis, Stephen N. (2005). "60. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas". In Brunton, Laurence L., Lazo, John S., Parker, Keith L. (eds.). Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill. p. 1636. ISBN 0-07-142280-3.
